ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform

Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potential ...
Business Insider

ProPhase Labs, Inc. Announces Commencement of Tender Offer to Repurchase Up to 1.7 Million Shares of Its Common Stock at Price of $2.30 Per Share

DOYLESTOWN, Pa., Nov. 20, 2017 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (www.ProPhaseLabs.com), a diversified natural health medical science company (the “Company” or “ProPhase”), today ...
Nasdaq

ProPhase Labs, Inc. (PRPH) Soars 11.2%: Is Further Upside Left in the Stock?

ProPhase Labs, Inc. PRPH shares soared 11.2% in the last trading session to close at $8.13. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Seeking Alpha

ProPhase Labs: Hidden Gem With An AI Kicker

ProPhase Labs is a diversified biotech company with profitable existing product lines and plans for expansion. The company's subsidiary, Nebula Genomics, offers whole genome sequencing and plans to ...
Investing

ProPhase Labs stock hits 52-week low at $2.02

In a challenging market environment, ProPhase Labs, Inc. (PRPH) stock has touched a 52-week low, dipping to $2.02. This price level reflects a significant downturn for the company, which has seen its ...